Denali Therapeutics Inc (DNLI)
$24.1
+0.01
(+0.04%)▲
Performance
- $23.87$24.88$24.10
0.95%
Downside
Day's Volatility :4.06%
Upside
3.14%
- $14.56$28.75$24.10
39.59%
Downside
52 Weeks Volatility :49.36%
Upside
16.17%
Returns
| Period | Denali Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 56.12% | 6.5% | 0.0% |
6 Months | 42.8% | 7.1% | 0.0% |
1 Year | -13.59% | 9.8% | 0.0% |
3 Years | -55.5% | 14.2% | -20.2% |
Highlights
Market Capitalization | 3.4B |
Book Value | $10.21 |
Earnings Per Share (EPS) | -0.96 |
Wall Street Target Price | 39.43 |
Profit Margin | -46.46% |
Operating Margin TTM | -70.46% |
Return On Assets TTM | -8.7% |
Return On Equity TTM | -11.33% |
Revenue TTM | 295.4M |
Revenue Per Share TTM | 2.1 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -250.3M |
EBITDA | -207.2M |
Diluted Eps TTM | -0.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.68 |
EPS Estimate Next Year | -2.59 |
EPS Estimate Current Quarter | -0.7 |
EPS Estimate Next Quarter | -0.66 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 63.61%
Technicals Summary
Sell
Neutral
Buy
Denali Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Denali Therapeutics Inc | 9.5% | 42.8% | -13.59% | -55.5% | 13.74% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Denali Therapeutics Inc | NA | NA | NA | -2.68 | -0.11 | -0.09 | NA | 10.21 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Denali Therapeutics Inc | Buy | $3.4B | 13.74% | NA | -46.46% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Denali Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 294.12M → -305.04M (in $), with an average decrease of 12137.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -119.47M → -101.80M (in $), with an average increase of 17.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 75.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 242.0%
Institutional Holdings
Baillie Gifford & Co Limited.
9.85%BlackRock Inc
8.55%Vanguard Group Inc
7.69%Wellington Management Company LLP
5.80%State Street Corporation
4.43%Capital Research Global Investors
4.24%
Corporate Announcements
Denali Therapeutics Inc Earnings
Denali Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Organization | Denali Therapeutics Inc |
Employees | 375 |
CEO | Dr. Ryan J. Watts Ph.D. |
Industry | Health Technology |
